| Trial ID: | L0219 |
| Source ID: | NCT05735197
|
| Associated Drug: |
Dapagliflozin 10mg Tab
|
| Title: |
Effect of Dapagliflozin on Renal Outcomes and Bone Mineral Disease in Non-diabetic Chronic Kidney Disease Patients
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Kidney Diseases|Bone Diseases, Metabolic
|
| Interventions: |
DRUG: Dapagliflozin 10mg Tab|DRUG: Placebo
|
| Outcome Measures: |
Primary: Effect of dapagliflozin on CKD progression, effect of Dapagliflozin on eGFR (ml/min), 1 year|Effect of dapagliflozin on Bone, effect on serum levels of bone turnover markers measured by ELISA, 1 year|Effect of dapagliflozin on minerals, effect of Dapagliflozin on calcium, phosphorus and magnesium, 1 year|Effect of dapagliflozin on BMD, assess Bone mineral disease (BMD) by using quantitative CT (QCT), 1 year | Secondary: Effect of dapagliflozin on blood pressure, follow up systolic and diastolic blood pressure throughout the study, 1 year
|
| Sponsor/Collaborators: |
Sponsor: Mansoura University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
100
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION
|
| Start Date: |
2022-09-01
|
| Completion Date: |
2023-11-01
|
| Results First Posted: |
|
| Last Update Posted: |
2024-11-08
|
| Locations: |
Urology and Nephrology center, Mansoura University, Mansoura, Aldakahliya, 35511, Egypt
|
| URL: |
https://clinicaltrials.gov/show/NCT05735197
|
